New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal M...(t was observed in the MTN study. IPM and...),Health

Date:2/9/2009

t was observed in the MTN study. IPM and others are now testing a new generation of microbicide candidates that contain highly potent antiretrovirals (ARVs) that specifically target HIV. These ARV microbicides are based on the same antiretroviral drugs being used successfully in HIV treatment and to prevent mother-to-child transmission of HIV. These next-generation microbicides are following the lead of treatments that have been successfully adapted to life-saving prevention methods for other diseases, including malaria, influenza and pneumonia. Next-generation microbicide candidates are in safety and early efficacy studies in a variety of countries in Europe, North America, and Africa. We need to test these candidate products both as single drugs and in combinations to see which approach is the most viable.

We also know from the contraceptive field that the more choices a woman has to protect herself, the more likely she will be able to use one of them for protection. IPM and others are conducting numerous product acceptability studies in Africa to help determine what types of products women really want and would use. Some women might like a gel used around the time of sex, others a product used once a day or even a vaginal ring that protects for up to 30 days at a time, and still others might prefer a vaginal film. Expanding microbicide formulation options in addition to coitally used gels is a promising next step in HIV prevention.

The need for microbicides remains clear, with 17.7 million women living with HIV globally and thousands more infected every day. And women urgently need prevention options they can initiate and control.

IPM applauds the leadership and ongoing resolve of the national governments that host these studies, the women who volunteer to participate, the donors who provide financial support, private sector partners who contribute promising drugs, our scientific colleagues who lend their expert
'/>"/>

SOURCE The International Partnership for Microbicides Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. New Research Suggests Platelet Stickiness May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease
2. Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
3. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
4. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
5. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
7. More Findings on Gene Involved in Childhood Asthma
8. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
9. VAI Findings Could Aid Diagnosis and Treatment of Several Types of Kidney Cancer
10. Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention
11. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models